Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List
The firm has a $338 price target on the company, a potential 17% upside from the stock's previous closing price.

Biogen Inc. (BIIB) shares were up 1.38% to $292.62 in early morning trading Monday after the company was added to Goldman Sachs "conviction buy" list Wednesday. 

The firm has a $338 price target on the company, which represents a potential 17% upside from the stock's previous closing price. 

"On BIIB's base [multiple sclerosis] franchise, we view investor concerns on competition and pricing as overblown," the firm said. "Finally, BIIB has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow."

Watch More with TheStreet:

More from Stocks

5 Things Investors Should Read Before Coming Earnings Season Blowout

5 Things Investors Should Read Before Coming Earnings Season Blowout

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

In Trump Era, Managing JPMorgan Is As Unpredictable As a Midnight Tweet

Video: Don't Underestimate China's Strength in a Trade War

Video: Don't Underestimate China's Strength in a Trade War

Tesla: What Are Wall Street's Best Analysts Saying Now?

Tesla: What Are Wall Street's Best Analysts Saying Now?

Master Limited Partnerships: A Badly Missed Investment Opportunity?

Master Limited Partnerships: A Badly Missed Investment Opportunity?